Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

2. Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies.

Just days after the FDA approved AstraZeneca and Daiichi Sankyo's Enhertu for a potentially lucrative new use, the regulatory has now cleared a diagnostic test that could help unlock the drug's ...

Many market commentators will tell you the stock market has never been so dangerously overconcentrated in so few stocks.

It's been a rough week for Tesla stock (TSLA). Shares of the EV giant were on track for a weekly loss of nearly 9% after a third-party report pointed to a slump in China deliveries. Tesla's sales ...

Some metrics suggest that a market downturn could be around the corner. Regardless of when the next bear market begins, it's important to start preparing now. The more steps you take right now ...

In the 557-patient study, Enhertu reduced the risk of disease progression or death by 50%, whilst improving overall survival by 36% compared to chemotherapy – translating to an extra half year ...

In other corporate news, Salesforce (CRM) stock slipped following the software giant's announcement on management changes. Honeywell (HON) shares fell after the conglomerate confirmed it will ...